Synthetic analogues of the parasitic worm product ES-62 reduce disease development in in vivo models of lung fibrosis

Colin J. Suckling, Sambuddho Mukherjee, Abedawn I. Khalaf, Ashwini Narayan, Fraser J. Scott, Sonal Khare, Saravanakumar Dhakshinamoorthy, Margaret M. Harnett, William Harnett

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Parasitic worms are receiving much attention as a potential new therapeutic approach to treating autoimmune and allergic conditions but concerns remain regarding their safety. As an alternative strategy, we have focused on the use of defined parasitic worm products and recently taken this one step further by designing drug-like small molecule analogues of one such product, ES-62, which is anti-inflammatory by virtue of covalently attached phosphorylcholine moieties. Previously, we have shown that ES-62 mimics are efficacious in protecting against disease in mouse models of rheumatoid arthritis, systemic lupus erythematosus and skin and lung allergy. Given the potential role of chronic inflammation in fibrosis, in the present study we have focused our attention on lung fibrosis, a debilitating condition for which there is no cure and which in spite of treatment slowly gets worse over time. Two mouse models of fibrosis - bleomycin-induced and LPS-induced - in which roles for inflammation have been implicated were adopted. Four ES-62 analogues were tested – 11a and 12b, previously shown to be active in mouse models of allergic and autoimmune disease and 16b and AIK-29/62 both of which are structurally related to 11a. All four compounds were found to significantly reduce disease development in both fibrosis models, as shown by histopathological analysis of lung tissue, indicating their potential as treatments for this condition.
LanguageEnglish
Pages212-218
Number of pages7
JournalActa Tropica
Volume185
Early online date23 May 2018
DOIs
Publication statusPublished - 30 Sep 2018

Fingerprint

Helminths
fibrosis
helminths
Fibrosis
lungs
Lung
animal models
inflammation
Inflammation
lupus erythematosus
Phosphorylcholine
rheumatoid arthritis
disease models
autoimmune diseases
Bleomycin
skin (animal)
hypersensitivity
Systemic Lupus Erythematosus
Autoimmune Diseases
Rheumatoid Arthritis

Keywords

  • drug development
  • fibrosis
  • ES-62
  • immunomodulation
  • parasitic worm

Cite this

Suckling, Colin J. ; Mukherjee, Sambuddho ; Khalaf, Abedawn I. ; Narayan, Ashwini ; Scott, Fraser J. ; Khare, Sonal ; Dhakshinamoorthy, Saravanakumar ; Harnett, Margaret M. ; Harnett, William. / Synthetic analogues of the parasitic worm product ES-62 reduce disease development in in vivo models of lung fibrosis. In: Acta Tropica. 2018 ; Vol. 185. pp. 212-218.
@article{94779006e83c4daa8bf33c2aaa9fe50e,
title = "Synthetic analogues of the parasitic worm product ES-62 reduce disease development in in vivo models of lung fibrosis",
abstract = "Parasitic worms are receiving much attention as a potential new therapeutic approach to treating autoimmune and allergic conditions but concerns remain regarding their safety. As an alternative strategy, we have focused on the use of defined parasitic worm products and recently taken this one step further by designing drug-like small molecule analogues of one such product, ES-62, which is anti-inflammatory by virtue of covalently attached phosphorylcholine moieties. Previously, we have shown that ES-62 mimics are efficacious in protecting against disease in mouse models of rheumatoid arthritis, systemic lupus erythematosus and skin and lung allergy. Given the potential role of chronic inflammation in fibrosis, in the present study we have focused our attention on lung fibrosis, a debilitating condition for which there is no cure and which in spite of treatment slowly gets worse over time. Two mouse models of fibrosis - bleomycin-induced and LPS-induced - in which roles for inflammation have been implicated were adopted. Four ES-62 analogues were tested – 11a and 12b, previously shown to be active in mouse models of allergic and autoimmune disease and 16b and AIK-29/62 both of which are structurally related to 11a. All four compounds were found to significantly reduce disease development in both fibrosis models, as shown by histopathological analysis of lung tissue, indicating their potential as treatments for this condition.",
keywords = "drug development, fibrosis, ES-62, immunomodulation, parasitic worm",
author = "Suckling, {Colin J.} and Sambuddho Mukherjee and Khalaf, {Abedawn I.} and Ashwini Narayan and Scott, {Fraser J.} and Sonal Khare and Saravanakumar Dhakshinamoorthy and Harnett, {Margaret M.} and William Harnett",
year = "2018",
month = "9",
day = "30",
doi = "10.1016/j.actatropica.2018.05.015",
language = "English",
volume = "185",
pages = "212--218",
journal = "Acta Tropica",
issn = "0001-706X",

}

Synthetic analogues of the parasitic worm product ES-62 reduce disease development in in vivo models of lung fibrosis. / Suckling, Colin J.; Mukherjee, Sambuddho; Khalaf, Abedawn I.; Narayan, Ashwini; Scott, Fraser J.; Khare, Sonal; Dhakshinamoorthy, Saravanakumar; Harnett, Margaret M.; Harnett, William.

In: Acta Tropica, Vol. 185, 30.09.2018, p. 212-218.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Synthetic analogues of the parasitic worm product ES-62 reduce disease development in in vivo models of lung fibrosis

AU - Suckling, Colin J.

AU - Mukherjee, Sambuddho

AU - Khalaf, Abedawn I.

AU - Narayan, Ashwini

AU - Scott, Fraser J.

AU - Khare, Sonal

AU - Dhakshinamoorthy, Saravanakumar

AU - Harnett, Margaret M.

AU - Harnett, William

PY - 2018/9/30

Y1 - 2018/9/30

N2 - Parasitic worms are receiving much attention as a potential new therapeutic approach to treating autoimmune and allergic conditions but concerns remain regarding their safety. As an alternative strategy, we have focused on the use of defined parasitic worm products and recently taken this one step further by designing drug-like small molecule analogues of one such product, ES-62, which is anti-inflammatory by virtue of covalently attached phosphorylcholine moieties. Previously, we have shown that ES-62 mimics are efficacious in protecting against disease in mouse models of rheumatoid arthritis, systemic lupus erythematosus and skin and lung allergy. Given the potential role of chronic inflammation in fibrosis, in the present study we have focused our attention on lung fibrosis, a debilitating condition for which there is no cure and which in spite of treatment slowly gets worse over time. Two mouse models of fibrosis - bleomycin-induced and LPS-induced - in which roles for inflammation have been implicated were adopted. Four ES-62 analogues were tested – 11a and 12b, previously shown to be active in mouse models of allergic and autoimmune disease and 16b and AIK-29/62 both of which are structurally related to 11a. All four compounds were found to significantly reduce disease development in both fibrosis models, as shown by histopathological analysis of lung tissue, indicating their potential as treatments for this condition.

AB - Parasitic worms are receiving much attention as a potential new therapeutic approach to treating autoimmune and allergic conditions but concerns remain regarding their safety. As an alternative strategy, we have focused on the use of defined parasitic worm products and recently taken this one step further by designing drug-like small molecule analogues of one such product, ES-62, which is anti-inflammatory by virtue of covalently attached phosphorylcholine moieties. Previously, we have shown that ES-62 mimics are efficacious in protecting against disease in mouse models of rheumatoid arthritis, systemic lupus erythematosus and skin and lung allergy. Given the potential role of chronic inflammation in fibrosis, in the present study we have focused our attention on lung fibrosis, a debilitating condition for which there is no cure and which in spite of treatment slowly gets worse over time. Two mouse models of fibrosis - bleomycin-induced and LPS-induced - in which roles for inflammation have been implicated were adopted. Four ES-62 analogues were tested – 11a and 12b, previously shown to be active in mouse models of allergic and autoimmune disease and 16b and AIK-29/62 both of which are structurally related to 11a. All four compounds were found to significantly reduce disease development in both fibrosis models, as shown by histopathological analysis of lung tissue, indicating their potential as treatments for this condition.

KW - drug development

KW - fibrosis

KW - ES-62

KW - immunomodulation

KW - parasitic worm

UR - https://www.sciencedirect.com/journal/acta-tropica

U2 - 10.1016/j.actatropica.2018.05.015

DO - 10.1016/j.actatropica.2018.05.015

M3 - Article

VL - 185

SP - 212

EP - 218

JO - Acta Tropica

T2 - Acta Tropica

JF - Acta Tropica

SN - 0001-706X

ER -